汇仁HUIREN品牌怎么样 申请店铺

我要投票 汇仁HUIREN在乌鸡白凤丸行业中的票数:278 更新时间:2025-04-20
汇仁HUIREN是哪个国家的品牌?「汇仁HUIREN」是 汇仁集团有限公司旗下著名品牌。该品牌发源于江西,由创始人陈冰郎在1996期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力汇仁HUIREN品牌出海!通过在本页面挂载汇仁HUIREN品牌的产品链接和联系邮箱,可以提高汇仁HUIREN产品曝光!跨境电商爆单神器,目前只要100元/年哦~

汇仁HUIREN怎么样

汇仁集团创建于1992年,是一家按健康产业链拓展,产学研相结合,科工贸一体化,集成式发展的中国大型医药企业集团。总部位于历史名城江西南昌,现有员工4000余人,总占地面积约80万平方米,总资产超过20亿元。

汇仁集团秉承“仁者爱人”的核心理念,走出了一条独具特色的健康产业的发展之路,企业综合经济实力快速提升,2008年销售收入突破42亿元。跻身于江西省工业竞争力企业、中国工业行业排头兵企业、中国影响力民营企业等行列。“汇仁”商标被评为“驰名保护”和“中国医药行业影响力品牌”。集团总裁陈年代连续当选为十届、十一届全国人民代表大会代表。

汇仁集团坚持“致力振兴民族医药”和“科技是第一生产力”的发展观念,投巨资在中国药谷——上海张江高科技园区建设国家级研发中心,中心拥有向全国开放、国内规模最大的中试平台和一大批国际领先水平的仪器设施。先后引进了博士生导师、博士后、博士等二十多位高层次医药科研人才并建立了博士后工作站。几年来,完成了数十项药品研究开发任务,承担了十多项国家九五、十五科技攻关项目及多项国家级科研课题,与国家科技部生命科学发展中心、中国中医研究院、中国医药研究开发中心、中国医学科学院药用植物研究所、北京大学、中国药科大学、上海中医药大学等国内著名研究机构和院校保持良好的研究开发合作关系并取得了一大批研究成果。2005年,汇仁又在英国牛津科技园建立了欧洲研发中心。

强大的研发能力保证了汇仁产品的高品质和源源不断地推出疗效确切、价格低廉深受消费者欢迎的新产品。现在,汇仁已形成补益类、妇科儿科类、抗生素类、消化系统类、循环系统类中成药和化学药等10多个系列,9个剂型100多个规格的产品群。其中有10个产品拥有国家发明专利。

在全国,汇仁共有46个品种中药材GAP基地,总面积15000亩。按GAP要求建设的高标准、现代化的中药饮片厂可年产中药饮片15000吨。

2001年后,汇仁先后在江西、上海、郑州、深圳、哈尔滨等地收购和兴建了6家医药公司。位于江西南昌高新区的汇仁医药商业建有中部地区规模最大,配套设施最完备的医药仓储物流中心。短短的几年,汇仁医药商业已经雄踞江西医药商业首位,上海汇仁医药也已跻身上海医药商业前10名。

汇仁—一个伴随国家改革开放进程诞生发展起来的新兴企业。汇仁—一个融合中国人文传统与现代医药科技内涵的民族品牌。将继续秉承“仁者爱人”的核心理念,深耕中华大地,阔步走向世界。

Huiren group, founded in 1992, is a large pharmaceutical enterprise group in China, which is based on the development of health industry chain, the combination of production, learning and research, the integration of science, industry and trade, and the integrated development. Headquartered in Nanchang, Jiangxi, a historic city, with more than 4000 employees, the company covers an area of about 800000 square meters and total assets of more than 2 billion yuan. Huiren group adheres to the core concept of "benevolent people love others" and has embarked on a unique road to the development of health industry. The comprehensive economic strength of the enterprise has been improved rapidly. In 2008, its sales revenue exceeded 4.2 billion yuan. It has become one of the industrial competitive enterprises in Jiangxi Province, the leader of Chinese industrial industry, and the influential private enterprises in China. "Huiren" trademark is rated as "well-known protection" and "influential brand of Chinese pharmaceutical industry". Chen Shi, President of the group, was elected as the representative of the 10th and 11th National People's Congress. Huiren group adheres to the development concept of "striving to revitalize national medicine" and "science and technology is the first productivity". It has invested heavily in the construction of a national R & D center in Shanghai Zhangjiang High Tech Park, China Pharmaceutical valley. The center has the largest pilot test platform open to the whole country and a large number of international leading level instruments and facilities. More than 20 high-level medical research talents, including doctoral supervisor, postdoctoral and doctor, have been introduced and a postdoctoral workstation has been established. In recent years, it has completed dozens of drug research and development tasks, undertaken more than ten national science and technology research projects during the Ninth Five-Year Plan and the Tenth Five-Year Plan and many national scientific research projects, and cooperated with the life science development center of the Ministry of science and technology of the people's Republic of China, China Academy of traditional Chinese medicine, China Pharmaceutical Research and development center, Institute of medicinal plants of the Chinese Academy of Medical Sciences, Peking University, China Pharmaceutical University, Shanghai University of traditional Chinese medicine Many famous research institutions and colleges in China have maintained a good cooperative relationship in research and development and achieved a large number of research results. In 2005, Huiren established a European R & D center in Oxford Science Park, UK. The strong R & D ability ensures the high quality of Huiren products and continuously launch new products with precise curative effect and low price, which are popular with consumers. Now, Huiren has formed more than 10 series of products, including tonics, gynecology and pediatrics, antibiotics, digestive system, circulation system Chinese patent medicine and chemical medicine, and more than 100 specifications of 9 dosage forms. Among them, 10 products have national invention patents. In China, Huiren has 46 kinds of gap bases of traditional Chinese medicine with a total area of 15000 mu. According to gap requirements, the high standard and modern Chinese Herbal Pieces Factory can produce 15000 tons of Chinese herbal pieces per year. After 2001, Huiren successively acquired and built 6 pharmaceutical companies in Jiangxi, Shanghai, Zhengzhou, Shenzhen, Harbin and other places. Huiren pharmaceutical business, located in Nanchang high tech Zone, Jiangxi Province, has the largest medical storage and logistics center in the central region and the most complete supporting facilities. In just a few years, Huiren pharmaceutical business has ranked first in Jiangxi pharmaceutical business, and Shanghai Huiren pharmaceutical has also ranked in the top 10 of Shanghai Pharmaceutical business. Huiren - a new enterprise born and developed along with the process of national reform and opening up. Huiren is a national brand that integrates the Chinese cultural tradition and modern medical science and technology. We will continue to adhere to the core concept of "benevolent people love one another", deeply cultivate the land of China and stride towards the world.

本文链接: https://brand.waitui.com/ba570b826.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

第一资本获批收购Discover

美国联邦储备委员会和货币监理署近日宣布,已批准第一资本金融公司(Capital One)收购发现金融服务公司(Discover Financial Services)的申请。这一交易还将使第一资本间接收购Discover Bank。此前,第一资本于2024年2月20日首次宣布与Discover达成一项最终协议。根据该协议,第一资本将通过全股票交易收购Discover,交易价值为353亿美元。(界面新闻)

2小时前

中信证券:自主科技、受益欧洲资本开支扩张的板块等配置上将占优

中信证券研报表示,贸易战僵持阶段,超预期的刺激和基于妥协的贸易协议都很难发生;僵持阶段比的是两国的经济韧性,中国的政策选项更多、空间更大、能耗更久,对美国而言,7月前大规模的国债到期可能会是特朗普关税政策的第一个动摇点;A股也是中国贸易战中提振信心的关键环节,应充分相信国家维护资本市场稳定的决心,港股可能是阶段性的薄弱环节,但也要看到内地资金依旧整体明显低配港股。配置上,从规避不确定性的角度,自主科技、受益欧洲资本开支扩张的板块、纯内需必选消费、稳定红利以及不依赖短期业绩的题材料将占优。(证券时报)

2小时前

盛和资源:MP公司暂停向中国出口稀土精矿不会对公司生产经营产生重大影响

4月20日,盛和资源(600392)发布公告称,网上出现“美国稀土生产商MP Materials(简称“MP公司”)宣布因关税停止向中国出口稀土精矿”的相关报道,公司就相关情况说明如下:2024年1月,MP公司与公司控股子公司盛和资源(新加坡)国际贸易有限公司再次续签了新的包销协议,盛和资源(新加坡)国际贸易有限公司为MP公司在中国的独家经销商;协议期限2年,到期后可延长1年;包销产品除稀土精矿外,还有其他稀土产品。截至目前,双方签署的包销协议尚在有效期内。目前因加征关税,MP公司暂时停止向中国出口稀土精矿。公司已构建了多元化的稀土原料供应渠道,四川矿、独居石以及其他国家进口矿可以作为替代供应。MP公司暂停向中国出口稀土精矿不会对公司生产经营产生重大影响。(新浪财经)

2小时前

华为将发布兆瓦级超充产品

华为将于4月22日召开2025华为智能电动&智能充电网络战略与新品发布会。据了解,发布会上,华为将发布兆瓦级超充产品。根据华为此前的预告,该兆瓦级充电产品最大充电电流2400安培,最大功率1.5兆瓦,每分钟能补给20度电,15分钟可充满一辆电动重卡(约300度电池容量)。(财联社)

2小时前

马来西亚航空考虑购买中国商飞飞机

据俄罗斯卫星社网站4月20日报道,马来西亚航空正在考虑购买中国国产飞机,中国商飞的三款商用机型C909、C919和C929都在评估范围内。马来西亚航空集团相关负责人18日对媒体表示,公司在制定未来几年的机队扩张计划,正密切评估购买中国商飞公司的飞机,双方团队已有过多轮沟通。报道称,被问及具体对C909、C919和C929中的哪款机型更感兴趣,该负责人表示,所有都在考虑之中,“我们在梳邦国际机场的运营就很适合商飞的小机型”。(界面新闻)

2小时前

本页详细列出关于天天乐的品牌信息,含品牌所属公司介绍,天天乐所处行业的品牌地位及优势。
咨询